WO2008016192A3 - Fused heterocyclic derivative and use thereof - Google Patents
Fused heterocyclic derivative and use thereof Download PDFInfo
- Publication number
- WO2008016192A3 WO2008016192A3 PCT/JP2007/065681 JP2007065681W WO2008016192A3 WO 2008016192 A3 WO2008016192 A3 WO 2008016192A3 JP 2007065681 W JP2007065681 W JP 2007065681W WO 2008016192 A3 WO2008016192 A3 WO 2008016192A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fused heterocyclic
- heterocyclic derivative
- cancer
- inhibitor
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/064,903 US8044049B2 (en) | 2006-08-04 | 2007-08-03 | Fused heterocyclic derivative and use thereof |
MX2009001349A MX2009001349A (en) | 2006-08-04 | 2007-08-03 | Fused heterocyclic derivative and use thereof. |
EP07792327.4A EP2049541B1 (en) | 2006-08-04 | 2007-08-03 | N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1h-pyrazole-5-carboxamide as vegfr inhibitor |
BRPI0714665-5A BRPI0714665A2 (en) | 2006-08-04 | 2007-08-03 | COMPOSITE, PRODUCT, PHARMACEUTICAL AGENT, AND METHOD FOR CANCER PROPHYLAXY OR TREATMENT |
AU2007279595A AU2007279595A1 (en) | 2006-08-04 | 2007-08-03 | Fused heterocyclic derivative and use thereof |
JP2009522492A JP5238697B2 (en) | 2006-08-04 | 2007-08-03 | Fused heterocyclic derivatives and uses thereof |
CA002659971A CA2659971A1 (en) | 2006-08-04 | 2007-08-03 | Fused heterocyclic derivative and use thereof |
US12/263,841 US20100168424A1 (en) | 2006-08-04 | 2008-11-03 | Fused heterocyclic derivative and use thereof |
US12/263,949 US8273741B2 (en) | 2006-08-04 | 2008-11-03 | Imidazo-pyridazinyl compounds and uses thereof |
US12/263,884 US8034812B2 (en) | 2006-08-04 | 2008-11-03 | Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof |
IL196799A IL196799A0 (en) | 2006-08-04 | 2009-01-29 | Fused heterocyclic derivative and use thereof |
NO20090986A NO20090986L (en) | 2006-08-04 | 2009-03-04 | Merged heterocyclic derivative and its use |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-213981 | 2006-08-04 | ||
JP2006213981 | 2006-08-04 | ||
JP2006-331230 | 2006-12-07 | ||
JP2006331230 | 2006-12-07 | ||
JP2007144072 | 2007-05-30 | ||
JP2007-144072 | 2007-05-30 |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/064,903 A-371-Of-International US8044049B2 (en) | 2006-08-04 | 2007-08-03 | Fused heterocyclic derivative and use thereof |
US12/263,949 Continuation US8273741B2 (en) | 2006-08-04 | 2008-11-03 | Imidazo-pyridazinyl compounds and uses thereof |
US12/263,841 Continuation US20100168424A1 (en) | 2006-08-04 | 2008-11-03 | Fused heterocyclic derivative and use thereof |
US12/263,884 Continuation US8034812B2 (en) | 2006-08-04 | 2008-11-03 | Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008016192A2 WO2008016192A2 (en) | 2008-02-07 |
WO2008016192A3 true WO2008016192A3 (en) | 2008-05-08 |
Family
ID=38996616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/065681 WO2008016192A2 (en) | 2006-08-04 | 2007-08-03 | Fused heterocyclic derivative and use thereof |
Country Status (18)
Country | Link |
---|---|
US (4) | US8044049B2 (en) |
EP (1) | EP2049541B1 (en) |
JP (1) | JP5238697B2 (en) |
KR (1) | KR20090047509A (en) |
AR (1) | AR062207A1 (en) |
AU (1) | AU2007279595A1 (en) |
BR (1) | BRPI0714665A2 (en) |
CA (1) | CA2659971A1 (en) |
CL (1) | CL2007002261A1 (en) |
CO (1) | CO6150183A2 (en) |
CR (1) | CR10607A (en) |
IL (1) | IL196799A0 (en) |
MA (1) | MA30651B1 (en) |
MX (1) | MX2009001349A (en) |
NO (1) | NO20090986L (en) |
PE (1) | PE20080538A1 (en) |
TW (1) | TW200817409A (en) |
WO (1) | WO2008016192A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102245609B (en) * | 2008-10-09 | 2016-03-09 | 百时美施贵宝公司 | Can be used as the Imidazopyridazine formonitrile HCN of kinase inhibitor |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR066845A1 (en) | 2007-06-05 | 2009-09-16 | Takeda Pharmaceutical | DERIVATIVES OF TRIAZOLOPIRIDINE AND IMIDAZOPIRIDINE A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER |
AU2008289101A1 (en) * | 2007-08-17 | 2009-02-26 | Icagen, Inc. | Heterocycles as potassium channel modulators |
US8431608B2 (en) * | 2007-08-17 | 2013-04-30 | Icagen Inc. | Heterocycles as potassium channel modulators |
US8324395B2 (en) | 2007-08-23 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
JP5394404B2 (en) * | 2008-02-06 | 2014-01-22 | ブリストル−マイヤーズ スクイブ カンパニー | Substituted imidazopyridazines useful as kinase inhibitors |
KR20100128305A (en) | 2008-02-28 | 2010-12-07 | 노파르티스 아게 | Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease |
CN101372475B (en) * | 2008-03-19 | 2012-01-04 | 南京工业大学 | Aromatic heterocyclic substituted acardite derivative and use thereof |
JPWO2009128520A1 (en) | 2008-04-18 | 2011-08-04 | 塩野義製薬株式会社 | Heterocyclic compounds having PI3K inhibitory activity |
WO2009136663A1 (en) * | 2008-05-08 | 2009-11-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
WO2010007099A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Limited | 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
UY32049A (en) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | CMET INHIBITORS |
CN102256964A (en) | 2008-10-02 | 2011-11-23 | 瑞斯比维特有限公司 | Compuestos inhibidores de quinasa map p38 |
GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
KR101634833B1 (en) | 2008-10-22 | 2016-06-29 | 어레이 바이오파마 인크. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
WO2010064611A1 (en) * | 2008-12-01 | 2010-06-10 | 武田薬品工業株式会社 | Heterocyclic compound and use thereof |
JO3101B1 (en) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | Benzothiazole derivatives as anticancer agents |
US8299074B2 (en) | 2008-12-11 | 2012-10-30 | Respivert Ltd. | P38 MAP kinase inhibitors |
EP2373625B1 (en) | 2008-12-24 | 2014-10-08 | Syngenta Limited | Methods for the preparation of aryl amides |
KR20110113755A (en) | 2009-02-10 | 2011-10-18 | 아스트라제네카 아베 | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer |
GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
WO2011137155A1 (en) | 2010-04-28 | 2011-11-03 | Bristol-Myers Squibb Company | Imidazopyridazinyl compounds and their uses for cancer |
CN103857395A (en) | 2011-04-01 | 2014-06-11 | 基因泰克公司 | Combinations of AKT inhibitor compounds and abiraterone, and methods of use |
EP2788345B1 (en) | 2011-12-09 | 2020-06-10 | Chiesi Farmaceutici S.p.A. | Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract |
EP2992112B1 (en) | 2013-04-22 | 2020-06-03 | Icahn School of Medicine at Mount Sinai | Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis |
CA2913417A1 (en) | 2013-05-30 | 2014-12-11 | Kala Pharmaceuticals, Inc. | Substituted n-(5-(2-aminoimidaz0[1,2-b]pyridazin-6-yloxy) derivatives a nd pharmaceutical compositions thereof useful for the treatment of diseases associated with abnormal angiogenesis and/or aberrant signaling of a growth factor |
JP2016540773A (en) * | 2013-12-06 | 2016-12-28 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CN115385741A (en) | 2013-12-13 | 2022-11-25 | 欧洲化学农业有限公司 | Fertilizer mixture containing nitrification inhibitor |
WO2016086026A1 (en) * | 2014-11-26 | 2016-06-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of a therapeutic compound and uses thereof |
US20180028667A1 (en) * | 2014-12-10 | 2018-02-01 | Senju Pharmaceutical Co., Ltd. | Aqueous liquid agent |
RU2751767C2 (en) | 2016-04-04 | 2021-07-16 | Локсо Онколоджи, Инк. | Liquid compositions (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidine-1-yl)pyrazolo[1,5-a]pyrimidine-3-yl)-3-hydroxypyrrolidine-1-arboxamide |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
LT3458456T (en) | 2016-05-18 | 2021-02-25 | Loxo Oncology, Inc. | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
JP2019519582A (en) | 2016-06-29 | 2019-07-11 | オリオン コーポレーション | Benzodioxane derivative and its pharmaceutical use |
JOP20190092A1 (en) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF |
EP3541431B1 (en) * | 2016-11-16 | 2024-04-17 | The General Hospital Corporation | Myeloperoxidase imaging agents |
US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US20220229072A1 (en) | 2019-06-04 | 2022-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
WO2021075477A1 (en) * | 2019-10-16 | 2021-04-22 | 国立大学法人京都大学 | Motor neuron degeneration inhibitor |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2022192732A1 (en) * | 2021-03-12 | 2022-09-15 | Gt Molecular, Llc | Multiplexed genotyping assays with a single probe using fluorescent amplitude tuning |
CA3237696A1 (en) | 2021-11-08 | 2023-05-11 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
WO2024088379A1 (en) * | 2022-10-27 | 2024-05-02 | 香港科技大学 | Tumor treatment or prevention method |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007013673A1 (en) * | 2005-07-29 | 2007-02-01 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
WO2007025090A2 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
WO2007025540A2 (en) * | 2005-09-02 | 2007-03-08 | Bayer Schering Pharma Aktiengesellschaft | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, the production thereof, and use of the same as medicaments |
WO2007038314A2 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989001478A1 (en) | 1987-08-07 | 1989-02-23 | The Australian National University | ARYLOXY- AND ARALKYLTHIO-IMIDAZO[1,2-b]PYRIDAZINES |
WO1989001333A1 (en) | 1987-08-07 | 1989-02-23 | The Australian National University | IMIDAZO[1,2-b]PYRIDAZINES |
GB8719368D0 (en) * | 1987-08-15 | 1987-09-23 | Wellcome Found | Heterocyclic compounds |
JPH0820584A (en) | 1994-07-04 | 1996-01-23 | Takeda Chem Ind Ltd | Imidazole derivative and its use |
CO4950519A1 (en) | 1997-02-13 | 2000-09-01 | Novartis Ag | PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION |
EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
PL206627B1 (en) | 1999-01-22 | 2010-09-30 | Kirin Pharma Kk | Quinazoline derivative, its use and pharmaceutical composition |
CN100376567C (en) | 1999-11-05 | 2008-03-26 | 阿斯特拉曾尼卡有限公司 | Qinazoline derivs. as VEGF inhibitors |
EA005996B1 (en) | 2000-02-15 | 2005-08-25 | Сьюджен, Инк. | Pyrrole substituted 2-indolinone, pharmaceutical composition, method of modulating catalytic activity of protein kinase, method of prevention and treatment of disorders related to protein kinase |
ATE399766T1 (en) | 2000-10-20 | 2008-07-15 | Eisai R&D Man Co Ltd | AROMATIC HETEROCYCLES CONTAINING NITROGEN |
JP2003137785A (en) * | 2001-08-23 | 2003-05-14 | Takeda Chem Ind Ltd | Jnk activation inhibitor |
ATE362475T1 (en) | 2003-12-31 | 2007-06-15 | Schering Plough Ltd | FIGHTING PARASITES IN ANIMALS BY USING IMIDAZO(1,2-B)PYRIDAZINE DERIVATIVES |
US8030327B2 (en) * | 2004-11-08 | 2011-10-04 | Mds K.K. | Fused imidazole derivative |
EP1832588A4 (en) * | 2004-12-28 | 2009-09-02 | Takeda Pharmaceutical | Condensed imidazole compound and use thereof |
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
EP2058309A4 (en) * | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | Fused heterocyclic compound |
-
2007
- 2007-08-03 CL CL200702261A patent/CL2007002261A1/en unknown
- 2007-08-03 EP EP07792327.4A patent/EP2049541B1/en active Active
- 2007-08-03 AR ARP070103435A patent/AR062207A1/en unknown
- 2007-08-03 KR KR1020097004527A patent/KR20090047509A/en not_active Application Discontinuation
- 2007-08-03 TW TW096128518A patent/TW200817409A/en unknown
- 2007-08-03 MX MX2009001349A patent/MX2009001349A/en unknown
- 2007-08-03 CA CA002659971A patent/CA2659971A1/en not_active Abandoned
- 2007-08-03 WO PCT/JP2007/065681 patent/WO2008016192A2/en active Application Filing
- 2007-08-03 PE PE2007001018A patent/PE20080538A1/en not_active Application Discontinuation
- 2007-08-03 JP JP2009522492A patent/JP5238697B2/en active Active
- 2007-08-03 BR BRPI0714665-5A patent/BRPI0714665A2/en not_active IP Right Cessation
- 2007-08-03 AU AU2007279595A patent/AU2007279595A1/en not_active Abandoned
- 2007-08-03 US US12/064,903 patent/US8044049B2/en active Active
-
2008
- 2008-11-03 US US12/263,949 patent/US8273741B2/en active Active
- 2008-11-03 US US12/263,841 patent/US20100168424A1/en not_active Abandoned
- 2008-11-03 US US12/263,884 patent/US8034812B2/en active Active
-
2009
- 2009-01-29 IL IL196799A patent/IL196799A0/en unknown
- 2009-02-09 CR CR10607A patent/CR10607A/en not_active Application Discontinuation
- 2009-02-17 MA MA31647A patent/MA30651B1/en unknown
- 2009-03-04 NO NO20090986A patent/NO20090986L/en not_active Application Discontinuation
- 2009-03-04 CO CO09022290A patent/CO6150183A2/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007013673A1 (en) * | 2005-07-29 | 2007-02-01 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
WO2007025090A2 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
WO2007025540A2 (en) * | 2005-09-02 | 2007-03-08 | Bayer Schering Pharma Aktiengesellschaft | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, the production thereof, and use of the same as medicaments |
WO2007038314A2 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
Non-Patent Citations (5)
Title |
---|
BARLIN G B ET AL: "Imidazo (1,2-b)pyridazines. II- 6-Alkylthio- and 6-Arylthio-3-methoxy-2-phenylimidazo(1,2-b)pyridazines", AUSTRALIAN JOURNAL OF CHEMISTRY, XX, XX, vol. 40, 1987, pages 1491 - 1497, XP009095679, ISSN: 0004-9425 * |
BARLIN G B ET AL: "Imidazo(1,2-b)pyridazines. IV. Synthesis and Central Nervous System Activities of Some 3-Methoxy-6-phenoxy(substituted phenoxy and naphthyloxy)-2-phenylimidazo(1,2-b)pyridazines", AUSTRALIAN JOURNAL OF CHEMISTRY, XX, XX, vol. 41, 1988, pages 1735 - 1742, XP009095689, ISSN: 0004-9425 * |
BULLOCK A N ET AL: "Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in Moloney Murine Leukemia Virus (PIM-1) Kinase", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 48, no. 24, 27 October 2005 (2005-10-27), pages 7604 - 7614, XP002405453, ISSN: 0022-2623 * |
MOURAD AE ET AL: "synthesis of imidazo[1,2-b]pyridazines: fenbendazole, oxifenbendazole analogs and related derivatives", JOURNAL OF HETEROCYCLIC CHEMISTRY, HETEROCORPORATION. PROVO, US, vol. 30, October 1993 (1993-10-01), pages 1365 - 1372, XP002331979, ISSN: 0022-152X * |
TREBSE, P. ET AL.: "A direct conversion of 5,6,7,8-Tetrahydro-2H-1-BenzoPyran-2,5-diones into substituted 1-Amino-5,6,7,8-Tetrahydroquinoline-2,5-diones", HETEROCYCLES, vol. 59, no. 1, 2003, pages 129 - 136, XP001537844 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102245609B (en) * | 2008-10-09 | 2016-03-09 | 百时美施贵宝公司 | Can be used as the Imidazopyridazine formonitrile HCN of kinase inhibitor |
Also Published As
Publication number | Publication date |
---|---|
US8044049B2 (en) | 2011-10-25 |
AR062207A1 (en) | 2008-10-22 |
EP2049541B1 (en) | 2015-09-23 |
AU2007279595A1 (en) | 2008-02-07 |
MA30651B1 (en) | 2009-08-03 |
CL2007002261A1 (en) | 2008-05-02 |
US20090306374A1 (en) | 2009-12-10 |
JP2009545583A (en) | 2009-12-24 |
MX2009001349A (en) | 2009-04-17 |
EP2049541A2 (en) | 2009-04-22 |
US20090137595A1 (en) | 2009-05-28 |
CA2659971A1 (en) | 2008-02-07 |
KR20090047509A (en) | 2009-05-12 |
US8034812B2 (en) | 2011-10-11 |
PE20080538A1 (en) | 2008-06-18 |
WO2008016192A2 (en) | 2008-02-07 |
US20100273788A1 (en) | 2010-10-28 |
TW200817409A (en) | 2008-04-16 |
CR10607A (en) | 2009-03-12 |
US20100168424A1 (en) | 2010-07-01 |
IL196799A0 (en) | 2009-11-18 |
CO6150183A2 (en) | 2010-04-20 |
NO20090986L (en) | 2009-05-04 |
JP5238697B2 (en) | 2013-07-17 |
BRPI0714665A2 (en) | 2012-03-13 |
US8273741B2 (en) | 2012-09-25 |
AU2007279595A2 (en) | 2009-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008016192A3 (en) | Fused heterocyclic derivative and use thereof | |
WO2009079008A8 (en) | Benzopyrans and analogs as rho kinase inhibitors | |
WO2011031554A3 (en) | Heterocyclic compounds as janus kinase inhibitors | |
WO2007042321A3 (en) | Kinase inhibitors | |
WO2013053983A8 (en) | Protein kinase inhibitors | |
WO2007105058A3 (en) | Pyrazole compounds | |
WO2007000339A8 (en) | Bicyclic derivatives as p38 kinase inhibitors | |
WO2008049919A3 (en) | Rho kinase inhibitors | |
RS54492B1 (en) | Apoptosis signal-regulating kinase inhibitor | |
WO2008083252A3 (en) | Methods of use for cyclopamine analogs | |
WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
TW200635918A (en) | Pharmaceutical compounds | |
UA109775C2 (en) | N-containing heteroaryl derivatives as JAK3 kinase inhibitors | |
WO2006134317A8 (en) | Oxadiazole derivatives as dgat inhibitors | |
TW200833675A (en) | Nicotinamide derivatives | |
WO2010151710A3 (en) | Substituted heterocyclic compounds as kinases inhibitors and method of use thereof | |
WO2008022286A3 (en) | Small molecule inhibitors of kynurenine-3-monooxygenase | |
WO2008055013A3 (en) | 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase | |
WO2012044727A3 (en) | Manufacturing process for pyrimidine derivatives | |
MX2009007302A (en) | Purine derivatives. | |
WO2011079230A3 (en) | Heterocyclic compounds as janus kinase inhibitors | |
TW200740776A (en) | N-phenylbenzotriazolyl c-kit inhibitors | |
WO2008155666A3 (en) | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | |
TNSN08494A1 (en) | Spirocyclic nitriles as protease inhibitors | |
WO2007000340A3 (en) | Bicyclic derivatives as p38 kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780037107.1 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12064903 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009010103 Country of ref document: EG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007792327 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2659971 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009522492 Country of ref document: JP Ref document number: 12009500231 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/001349 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2009-010607 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 574953 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007279595 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 813/KOLNP/2009 Country of ref document: IN Ref document number: 1020097004527 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2009107705 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11139 Country of ref document: GE Ref document number: 09022290 Country of ref document: CO Ref document number: A20090295 Country of ref document: BY |
|
ENP | Entry into the national phase |
Ref document number: PI0714665 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090203 |